Relationship of Fusobacterium nucleatum levels in gut microbiota with type 2 diabetes mellitus in Uygurs of Xinjiang

Abstract

Abstract:

AIM: To detect the levels of Fusobacterium nucleatum in Uygurs of Xinjiang with normal glucose tolerance (NGT) or type 2 diabetes mellitus (T2DM) and to analyze the correlation between Fusobacterium nucleatum level and type 2 diabetes mellitus. METHODS: Blood and fecal samples were collected from Uygurs of Xinjiang with NGT or T2DM respectively. 16SrDNA quantitative real-time PCR technology was used to detect the levels of Fusobacterium nucleatum in fecal samples. The correlations between Fusobacterium nucleatum and BMI, TC, TG, HDL and LDL levels were analyzed by Pearson. RESULTS: (1) The levels of Fusobacterium nucleatum in Uygurs T2DM group were significantly higher than those in Uygurs NGT group (P=0.011). (2) Fusobacterium nucleatum was positively correlated with the levels of BMI (r=0.335, P=0.049), TC (r=0.472, P=0.011) and LDL (r=0.368, P=0.029). CONCLUSION: The levels of Fusobacterium nucleatum may be closely related to lipid metabolism of T2DM in Uygurs.

Key words: Fusobacterium nucleatum, type 2 diabetes mellitus, quantitative real-time PCR

CLC Number:

R587.1

WANG Chanyue, WANG Ye, ZHANG Peipei, CHEN Mingyue, YANG Hao, ZHU Manli, LI Linlin. Relationship of Fusobacterium nucleatum levels in gut microbiota with type 2 diabetes mellitus in Uygurs of Xinjiang[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1321-1325.

References

［1］Membrez M, Blancher F, Jaquet M, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice［J］. FASEB J, 2008, 22(7):2416-2426.
［2］Xu J, Lian F, Zhao L, et al. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula［J］. ISME J, 2015, 9(3): 552-562.
［3］Wang J, Huang T, Zhang C, et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice［J］. ISME J, 2015, 9(1): 1-15.
［4］Larsen N, Vogensen FK, FW Van, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults［J］. Plos One, 2010, 5(2): e9085.
［5］Karlsson FH, Tremaroli V. Gut metagenome in European women with normal, impaired and diabetic glucose control［J］. Nature, 2013, 498(7452): 99-103.
［6］Larsen N, Vogensen FK, FW Van, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults［J］. Plos One, 2010, 5(2): e9085.
［7］Wu X, Ma C, Han L, et al. Molecular characterisation of the faecal microbiota inpatients with type II diabetes［J］. Curr Microbiol, 2010, 61(1): 69-78.
［8］Storm JC, Ford BA, Streit JA. Myocardial infection due to fusobacterium nucleatum［J］. Diagn Microbiol Infect Dis, 2013, 77(4): 373-375.
［9］Chew J, Zilm PS, Fuss JM, et al. A proteomic investigation of fusobacterium nucleatum alkaline-induced biofilms［J］. BMC Microbiol, 2012, 12: 189.
［10］Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice［J］. ISME J, 2013, 7(4): 880-884.
［11］Mccoy AN, Araújo-Prez F, Azcrate-Peril A, et al. Fusobacterium is associated with colorectal adenomas［J］. Plos One, 2013, 8(1):1-8.
［12］Cairo F, Gaeta C, Dorigo W, et al. Periodontal pathogens in atheromatous plaques. A controlled clinical and laboratory trial［J］. J Period Res, 2004, 39(6): 442-446.
［13］Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment［J］. Cell Host Microbe, 2013, 14(2): 207-215.
［14］Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy［J］. Cell,2017,170(3):548-563.
［15］Han YW, Shi W, Huang GT, et al. Interactions between periodontal bacteria and human oral epithelial cells: Fusobacterium nucleatum adheres to and invades epithelial cells［J］. Infect Immun, 2000, 68(6): 3140-3146.
［16］ Park SR, Kim DJ, Han SH, et al. Diverse Toll-like receptors mediate cytokine production by fusobacterium nucleatum and aggregatibacter actinomycetemcomitans in macrophages［J］. Infect Immun, 2014, 82(5): 1914-1920.
［17］朱大龙．炎症与2型糖尿病［J］. 中国糖尿病杂志, 2006, 14(1): 73-74.
［18］殷薛飞, 刘晓慧, 申华莉, 等. 具核梭杆菌具核亚种蛋白质组及其在癌症pH环境下的差异蛋白质组分析［J］. 化学学报, 2015, 73(4): 337-342.
［19］洪珊珊, 钱荣立. 丁酸盐类可改善小鼠胰岛素敏感性并增加其能量消耗［J］. 中国糖尿病杂志, 2012, 10(1):41-41.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[4]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[5]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[6]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[7]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[8]	YE Shengkai, WEN Jie, LIU Weiping, REN Xia, CHEN Haiying, DU Ying, LI Xue, ZHANG Ru, YU Li, ZHANG Biying. Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 814-819.
[9]	ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72.
[10]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[11]	LIU Chang, JIANG Daoli, LIU Xiaofang, XU Jia, WANG Lijue, WANG Qian, XU Ling, FANG Yi. Establishment of rat model of type 2 diabetes induced by streptozotocin combined with cerebral ischemic reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 518-525.
[12]	NI Yingqun, XIE Fengtao, FANG Zhaohui. Danzhijiangtang capsule protects vasculopathy of T2DM: an evaluation based on the expression of Wnt/β-catenin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 531-537.
[13]	KONG Xiang, HUA Qiang, MENG Xiangjian, YAO Xinming, WANG Yong, XIA Libin. Clinical implications of circulating miRNA-101 expression level in patients with newly diagnosed type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1406-1409.
[14]	DONG Chao, WANG Tao, ZHOU Dongmei, WANG Ya, WANG Laicheng, LV Dongmei. Investigation and analysis of antidiabetic agents therapy in inpatients with type 2 diabetes mellitus in our hospital [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 87-91.
[15]	HUANG Qiong, ZHANG Liu-fu, CHENG Yan, SI Li, WEI Wei. Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 307-311.